•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
Canter Resources Grants Options
Should Value Investors Buy California Resources (CRC) Stock?
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
California Resources Corporation Schedules Third Quarter 2026 Earnings Conference Call
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio
Head to Head Comparison: California Resources (NYSE:CRC) versus Kinetik (NYSE:KNTK)
Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition
California Resources to Divest Uinta Basin Assets for $90 Million
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
California Resources Corporation Announces Divestiture of Uinta Basin Assets
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu
Why Is California Resources (CRC) Up 2.7% Since Last Earnings Report?
California Resources Completes $63M Acquisition of Crimson Midstream
California Resources Corporation Completes Acquisition of Crimson
Driving California's Energy Future: California Resources Corporation Releases 2025 Sustainability Update
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
CRC Down 14.1% in 3 Months: Can Cost Gains Turn It Around?